Zhou Wei, Founder Of TMT: Investing In Digital Medicine From The Perspective Of Technology, Focusing On The Multiplication Effect Brought By Technological Intervention.

"If there are 100 vertical directions in the field of health care, we can only vote for 5%-10%. We hope to get involved in the TMT perspective and solve the imbalance between supply and demand by using technology to achieve the multiplier effect. Recently, Zhou Wei, partner of Capital Partners of creative partners, said in an exclusive interview with the economic news reporters in twenty-first Century.

Founding partners capital was founded by Zhou Wei, the former KPCB managing partner and TMT team who worked together for many years, in 2017. The group's early mining investment companies include Jingdong, Yi Xin, Rong 360, Himalaya and so on, creating an early investment of 10 years and 30% projects for unicorn's success rate.

Less than a year and a half after the establishment of the new brand, genesis partners achieved the first IPO, an early investment company. At the same time, this group, which is well-known for its investment in TMT, has entered the digital medical field since 2018, and has invested in several technologies such as technology, cloud technology and Connaught letter.

"We still insist that we are TMT investment team." Zhou Wei emphasized that the focus of group investment in digital medicine is on digitization, focusing on the application of TMT technology in the medical industry.

Zhou Wei. Data map

In the view of Zhou Wei, Internet Co, which have grown up over the past 20 years, are constantly building up connections, between people, between business and commerce, between people and business. But not all problems can be solved by establishing a connection, especially in the medical field. Because of the shortage of resources in high-quality doctors' hospitals, the connection can not solve the fundamental problem.

Creative partners hope to find technical solutions to solve the problem of supply imbalance. At the same time, before and after 2018, many technologies such as AI, robotics and other technologies have gradually matured, enabling applications and large-scale commercialization in the medical field. As a result, the creation partners take digital medicine as one of the main concerns.

Zhou Wei concluded that when investing in digital medical projects, the creation partners follow three logics. First of all, technology intervention can bring high-quality supply and achieve multiplier effect. Second, the technology products are not only suitable for the top hospitals in the first tier cities, but also help the massive long tail hospitals and clinics in low cities and towns. Third, the product itself has a good capacity for large-scale commercialization.

In February 2019, genesis partners took part in the B round investment in AI technology. In fact, with the development of AI technology in recent years, the field of AI medical imaging has been developing very hot in recent years.

Zhou Wei explained that the choice of investment Kun, first of all because most of the AI medical imaging companies choose to assist in the diagnosis of pulmonary nodules, the number of Kun chose to do more difficult cardio cerebral vascular imaging AI. This differentiation enables the number of Kun to stand out in the homogenization competition.

Second, from the excellent AI technology to the landing application of products, it also tests the commercialization ability of the team. The number of Kun team itself has sales executives from IBM. They have very clear thinking about the landing of products. Thus, the founding partners invested in it.

The current development of AI medical imaging industry also confirms the judgement of the creation partner team. Many companies are getting financing and valuations rising, but they are slow to land and slow to make profits.

"At the bottom of the technology is almost the same situation, excellent commercial sales ability has become the difference between the number of Kun and other people's competition." Zhou Wei said. The number of Kun team has been relatively advanced in terms of commercialization, and its contract volume in the first 4 months of this year has even surpassed that of last year.

"When choosing a target company, the ability of the industry to be generic is not bad, and the essential characteristic part of the industry must also be strong. The character of logarithm Kun is the ability to commercialize. For other industries, the feature part may be in other ways. It is also a test for investors to grasp the characteristics. Zhou Wei added. In the future, creative partners will continue to focus on investment opportunities in medical robotics and AI in the field of drug research and development.

?